Ranbaxy acquires Bangalore vaccine firm

39820 Investors following Ranbaxy Labs. Share this News with them.

0

Like this story, share it with millions of investors on M3

Ranbaxy acquires Bangalore vaccine firm

Ranbaxy Laboratories on Tuesday signed an agreement to acquire product rights and manufacturing facility of Bangalore-based Biovel Lifesciences Pvt Ltd, for an undisclosed sum.

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Ranbaxy Dec PAT seen at Rs 396.2cr: P Lilladher Ranbaxy exits Chinese joint venture biz; stk down Ranbaxy sells entire stake in China JV Ranbaxy shares fall on FDA letter to unit Ranbaxy to launch hypertension drug in Africa ALSO READ See latest News about Ranbaxy Labs See previous management interviews See what other Experts & Brokerages are saying about Ranbaxy Labs Ranbaxy Labs BSE | NSE 28/05/12 Are Mutual Funds betting on Ranbaxy Labs?

Ranbaxy Laboratories on Tuesday signed an agreement to acquire product rights and manufacturing facility of Bangalore-based Biovel Lifesciences Pvt Ltd, for an undisclosed sum.

Biovel's development pipeline comprises of vaccines and biotherapeutics, the two companies said in a statement.

"This transaction with Biovel provides us an entry platform to manufacture vaccines as well as biotherapeutics. The vaccine and biotherapeutics business will be an important part of our growth strategy," Ranbaxy Chief Executive Atul Sobti said in the statement.

Ranbaxy is majority owned by Japan's Daiichi Sankyo.